Open AccessShort term efficacy and safety of low dose tolvaptan in patients with acute decompensated heart failure with hyponatremia: a prospective observational pilot study from a single center in South India
Author(s) -
Soumya Patra,
Bhupesh Kumar,
Kaushal Kumar Harlalka,
Anita Jain,
H M Bhanuprakash,
Kanchanahalli Siddegowda Sadananda,
Harsha Basappa,
Santhosh Kumar Kannath,
K S Rajith,
K S Bharathi,
CN Manjunath
Publication year - 2014
Publication title -
heart views
Language(s) - English
Resource type - Journals
eISSN - 0976-5123
pISSN - 1995-705X
DOI - 10.4103/1995-705x.132136
Subject(s) - tolvaptan , medicine , hyponatremia , heart failure , acute decompensated heart failure , hypernatremia , renal function , adverse effect , population , diuretic , cardiology , urology , sodium , chemistry , environmental health , organic chemistry
In acute decompensated heart failure (ADHF), diuretic use, the mainstay therapy for congestion, is associated with electrolyte abnormalities and worsening renal function. Vasopressin mediates fluid retention in heart failure. In contrast to diuretics, the vasopressin antagonist tolvaptan may increase net volume loss in heart failure without adversely affecting electrolytes and renal function. Hyponatremia (serum sodium concentration, <135 mEq/L) is a predictor of death among patients with heart failure.